Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07223840 · ClinicalTrials.gov registry record · Phase 2
A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse
A Phase 2 study of Smoking, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 222
- Enrollment target
- 20
- Study locations
NCT07223840 is a Phase 2 study of Smoking that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 222 participants, below the 453-participant average among 123 other Smoking trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT07223840, a Phase 2 study of Smoking, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 222 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluates the efficacy and safety of brenipatide when compared to placebo for reducing the risk of relapse to cigarette smoking in adults who have recently quit. Study participation will last approximately 34 weeks with up to 17 study visits, which includes a 2-week screening period, 24-week treatment period, 8-week safety follow-up period. .
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Brenipatide
Study Locations (20)
Florida
- Hillcrest Medical Research - DeLand
- TecTum Research - Hollywood
- K2 Medical Research ORLANDO - Maitland
- GTL Medical & Research Group - Miami
Texas
- FutureSearch Trials of Dallas - Dallas
- NextStage Clinical Research_Houston (07) -Menninger Clinic - Houston
- The University of Texas Health Science Center at Houston - Houston
Other
- Beijing Chaoyang Hospital, Capital Medical University - Beijing
- Beijing Anding Hospital - Affiliated Capital University of Medical Science - Beijing
- Sichuan Provincial People's Hospital - Chengdu
Arkansas
- Woodland Research Northwest - Rogers
Georgia
- North Georgia Clinical Research - Woodstock
Michigan
- Revival Research Institute, LLC - Dearborn
Missouri
- Arch Clinical Trials - St Louis
Nevada
- Vector Clinical Trials - Las Vegas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 222 participants |
| Start Date | 2025-11-03 |
| Est. Completion | 2027-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07223840
The ClinicalTrials.gov registry entry for NCT07223840 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 222 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 453-participant average among 123 other Smoking trials with a reported enrollment target (51% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smoking appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07223840 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Texas, Other.
Frequently Asked Questions
What is clinical trial NCT07223840 about?
NCT07223840 is a clinical study titled "A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse". This study evaluates the efficacy and safety of brenipatide when compared to placebo for reducing the risk of relapse to cigarette smoking in adults who have recently quit. Study participation will last approximately 34 weeks with up to 17 study visits, which includes a 2-week screening period, 24-...
What is the current status of trial NCT07223840?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 222 participants. The study started on 2025-11-03. Estimated completion is 2027-02.
What conditions does trial NCT07223840 study?
This clinical trial studies the following conditions: Smoking.
What interventions are being tested in trial NCT07223840?
The interventions under investigation include: Placebo (DRUG), Brenipatide (DRUG).
Who is sponsoring clinical trial NCT07223840?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07223840 being conducted?
This trial has 20 study locations across Arkansas, Florida, Georgia, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Potential of Kava in Enabling Tobacco Cessation - Its Holistic Effects in Managing Stress and Insomnia Associated With Abstinence
RECRUITING · Phase 2
-
App for Reducing Cravings to Smoke
RECRUITING · Phase 2
-
Reducing Tobacco-associated Lung Cancer Risk: A Randomized Clinical Trial of AB-free Kava
ACTIVE NOT RECRUITING · Phase 2
-
Proactive Health Intervention for Tobacco Users (Get PHIT)
COMPLETED · Phase 2
-
Computer-Assisted Intervention for Smoking During Pregnancy
COMPLETED · Phase 2
-
Oxidative Stress and Vitamin E Requirements
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.